CHF Solutions’ Aquadex Products Granted Federal Supply Schedule Contract
18 August 2020 - 10:00PM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
improving the lives of patients suffering from fluid overload,
today announced that its Aquadex™ product line has been added to
the Federal Supply Schedule, expanding access to all federal
government agencies, including the Department of Veterans Affairs
(VA), Indian Health Services (IHS) and Department of Defense (DOD)
Medical Treatment Facilities.
“Our goal is to provide access to the Aquadex therapy for all
patients suffering from fluid overload. The inclusion on the
Federal Supply Schedule is a significant milestone towards this
goal by streamlining the purchasing process and allowing the
therapy to be available for patients at all federal government
facilities,” said John Erb, CEO of CHF Solutions. “The Aquadex
SmartFlow ultrafiltration system is a simple, flexible and smart
fluid management platform that reduces fluid overload caused by a
variety of conditions, including heart failure, COVID-19 and other
critical care conditions. With this technology in hand, providers
can use ultrafiltration to help mitigate life-threatening
complications and manage their patients’ fluid balance with
precision, control and ease.”
The Aquadex system has been used at individual VA hospitals for
many years. In each case, the company has negotiated contracts with
each individual facility. Now, in partnership with Downeast
Logistics LLC, the Aquadex SmartFlow™ console and Aquadex FlexFlow®
Blood Circuit Set have been added to the federal supply contract
between Downeast Logistics and the federal government and is
approved for purchase by all facilities, thereby reducing the time
associated with approval at each individual facility.
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow™ system for ultrafiltration therapy. CHF
Solutions is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the reducing the approval process at
VA facilities. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our expectations regarding the potential
impacts of the COVID-19 pandemic on our business operations, our
ability to execute on our commercial strategy, the possibility that
we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2024 to May 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From May 2023 to May 2024